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ScienceDirectOnce considered an inevitable consequence of HIV treatment,
drug resistance is declining. This decline supports the
hypothesis that antiretroviral therapy can arrest replication and
prevent the evolution of resistance. Further support comes
from excellent clinical outcomes, the failure of treatment
intensification to reduce residual viremia, the lack of viral
evolution in patients on optimal therapy, pharmacodynamics
studies explaining the extraordinarily high antiviral activity of
modern regimens, and recent reports of potential cures.
Evidence supporting ongoing replication includes higher rates
of certain complications in treated patients and an increase in
circular forms of the viral genome after intensification with
integrase inhibitors. Recent studies also provide an explanation
for the observation that some patients fail protease-inhibitor
based regimens without evidence for resistance.
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Introduction
Not long after the introduction of the nucleoside analog
reverse transcriptase inhibitor (NRTI) zidovudine (AZT) as
the first antiretroviral drug for the treatment of HIV-1
infection, resistance to AZT was detected in treated
patients [1]. Since that time, resistance has been reported
for each new antiretroviral drug introduced [2], and the
field has been haunted by the specter of widespread and
inevitable drug resistance, necessitating the continued de-
velopment of new classes of antiretroviral drugs. However,
recent clinical experience suggests that HIV-1 drug resist-
ance is actually declining, and it is now becoming clear that
resistance is not an inevitable consequence of HIV-1 treat-
ment, but rather a reflection of suboptimal treatment.
Optimal therapy appears to prevent the evolution of resist-
ance, even over long time periods. This review will explore
the theoretical basis for this remarkable development.
The modern era of HIV-1 treatment began in 1997 when
two new classes of antiretroviral drugs were introduced,www.sciencedirect.com the non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and the protease inhibitors (PIs). Three drug
combinations consisting of an NNRTI or a PI and two
drugs from the NRTI class were tested in clinical trials
[3–5]. In these trials, it was shown for the first time that
combination antiretroviral therapy (ART) could reduce
viremia to clinically undetectable levels. When patients
start on an appropriate combination of three antiretroviral
drugs, plasma virus levels fall within a few months from
pre-therapy levels on the order of 104 to 105 copies of
genomic viral RNA/ml to below the limit of detection of
clinical assays (50 copies/ml). Clinically, the disappear-
ance of detectable viremia is associated with increases in
or preservation of CD4+ T cell counts and the reversal or
prevention of immunodeficiency. Combination ART
rapidly became the standard of care for HIV-1 infection
(Figure 1). Newly revised US treatment guidelines [6]
call for the treatment of all infected individuals with ART
regimens consisting of two NRTIs and either an NNRTI,
a PI, or an integrase strand transfer inhibitor (InSTI) [7,8].
Several recent studies suggest that patients who start
modern ART regimens early in the course of disease
have a near normal lifespan expectancy, even in resource
limited settings [9].
Although ART can suppress viremia to clinically
undetectable levels, there is inevitably a rebound in
viremia within several weeks after discontinuation of
therapy [10]. The ability of the virus to persist despite
ART is due at least in part to its ability to establish a state
of latent infection in resting memory CD4+ T cells
[11,12]. This latent reservoir is extremely stable, even
in patients on optimal ART [13–16], and is a likely source
of viral rebound following interruption of therapy [17].
Another important indication of viral persistence during
ART is the presence of trace levels of free virus in the
plasma [18–21]. This residual viremia is detectable with
RT-PCR assays that have single molecule sensitivity. All
current antiretroviral drugs act by blocking new infection
events rather than by blocking virus production by cells
that already have an integrated provirus (Figure 1). Thus,
the residual viremia may reflect the activation of latently
infected cells or possibly the release of virus from other
stable reservoirs [17]. The only exceptions to the rule of
viral rebound after discontinuation of ART are rare cases
of patients treated early in the course of infection who are
able to control viral replication through unknown immu-
nologic mechanisms [22,23].
The decline in HIV-1 drug resistance
HIV-1 drug resistance is a result of random mutations
introduced by the error prone HIV-1 reverse transcriptaseCurrent Opinion in Virology 2013, 3:487–494
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Antiretroviral therapy for HIV-1 infection. The steps in the life cycle blocked by different classes of antiretroviral drugs are indicated. Current ART
regimens consist of two NRTIs and either an NNRTI, a PI, or an InSTI. Inhibitors of HIV-1 entry, chemokine receptor antagonists and fusion inhibitors,
can also be used. Note that all current antiretroviral drugs act to prevent new cells from becoming infected. They do not block the production of virus
particles by a cell that already carries an integrated provirus. The PIs prevent virus particles from maturing to an infectious form. Immature virus
particles show defects at multiple downstream steps in the virus life cycle (dotted lines), including entry, reverse transcription, and integration. See text
for references.when it converts the single stranded genomic viral RNA
into double stranded DNA shortly after viral entry. On
average, one mutation is introduced in the 10 kb genome
for every three cycles of replication [24]. These mutations
are typically base substitutions although insertions, dupli-
cations and recombination can also occur. Because resist-
ance mutations arise during reverse transcription in newly
infected cells, the evolution of resistance can in principle
be arrested if new infection events are blocked by ART.
Avoiding resistance has been a major guiding principle of
ART, and recent studies suggest that this goal is actually
achievable.
Clinical experience and recent observational studies
indicate that the incidence and prevalence of HIV-1 drug
resistance is actually declining [25,26,27,28,29]. A
comprehensive study of essentially all infected individ-
uals in Sweden found a dramatic decrease in the preva-
lence of resistance between 2003 and 2007 with slower
decreases thereafter [25]. This decrease coincided with
the phase out of older drugs and the introduction of
newer classes of antiretroviral drugs. Most mutations
were found in patients with a history of suboptimal
treatment. The only worrying trend was a very slight
recent increase in the prevalence of NNRTI resistance
mutations, which was attributed to infection with resist-
ant viruses in low to middle income countries where
NNRTI regimens are very common and resistance
monitoring is absent. A large multicohort European study
found a decrease in the prevalence of drug resistance,Current Opinion in Virology 2013, 3:487–494 particularly multiclass resistance, beginning around 2005
and continuing through the study end date in 2008 [26].
In a large study of French patients with virologic failure
(two plasma HIV-1 measurements  > 50 copies/ml), the
fraction of samples with common RT resistance
mutations (M184V/I, K103N) declined in the period
between 2005 and 2010, despite continued use of drugs
that select those mutations (lamivudine and emtricita-
bine for M184V/I and efavirenz for K103N) [27]. The
authors attribute this decline to the use of single pill,
once a day regimens which promote improved adherence
and prevent differential adherence to components of a
regimen. Selection of the NRTI resistance mutation
K65R has also been declining despite the widespread
use of tenofovir, which selects this mutation [28]. The
prevalence of multidrug resistance has been declining in
Portugal in the time between 2001 and 2013 [29]. Over-
all, these studies suggest that improvements in ART,
including convenient single pill regimens consisting of
three relatively non-toxic drugs, have improved adher-
ence and allowed the full potential of ART to become
apparent.
The efficacy of modern ART regimens in suppressing
viral replication and preventing the evolution of resist-
ance is a major factor in recent change in HIV-1 treatment
guidelines. In the past, concern about resistance was often
cited as a reason for delaying the initiation of ART.
However, numerous studies have shown that early treat-
ment is associated with better outcomes (reviewed inwww.sciencedirect.com
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Table 1
Arguments for and against the hypothesis that ART can completely block HIV-1 replication and evolution (please see text for references)
For Against
Success of ART in controlling viral replication and
preventing immunodeficiency
Evidence for ongoing immune activation and inflammatory
state in treated pateints
Failure of intensification to reduce residual viremia Transient increase in 2LTR cirlecs with RAL intensification
Lack of evidence for sequence change over time in most patients Sequence evolution in a subset of pateints
Pharmacodynamic data indicating extremely high
antiviral activity of NNRTIs and PIs
Cell to cell spread reduces antiviral effect
Recent reports of cure[6]), and with the high antiviral activity and improved
toxicity profiles of modern regimens, there is no medical
reason to delay treatment. Thus, current US guidelines
recommend treating all infected individuals with ART.
The debate over ongoing viral replication
The dramatic success of ART suggests that viral replica-
tion, and hence viral evolution, can be completely
blocked in adherent patients. However, a vigorous debate
over whether ART can completely inhibit viral replica-
tion has raged for several years. Table 1 lists the major
arguments supporting and contradicting the hypothesis
that ART can completely block HIV-1 replication and the
evolution of resistance. Because of the large number of
people currently being treated with ART, there is an
enormous amount of clinical data that pertains to this
question. Careful analysis by committees that set treat-
ment guidelines has shown that early initiation of treat-
ment is associated with the best outcomes in HIV-1
infection [6]. There is no evidence that adherent
patients spontaneously fail treatment with resistant virus.
There is very strong evidence that in untreated patients,
ongoing viral replication in each infected individual leads
to diversification of a single infecting founder virus into a
complex quasispecies that shows progressive divergence
from the founder virus over time. The error prone nature
of reverse transcriptase results in an inevitable linkage
between viral replication and viral evolution. In response
to the selective pressure exerted by the immune response
or suboptimal drug treatment, escape or resistance
mutations arise very rapidly (within weeks). The success
of treatment, together with the dramatic decline in resist-
ance described above, argues strongly that ART can halt
clinically significant viral replication and hence viral
evolution.
Interventional studies involving treatment intensification
also support the conclusion that ART stops viral replica-
tion. As discussed above, patients on ART who have
suppression of viremia to below the limit of detection
of clinical assays do have trace levels of free virus in the
blood that can be detected with extremely sensitive
‘single copy’ assays [18–21]. If the residual viremia is a
reflection of ongoing viral replication not fully suppressed
by ART, then the addition of a fourth antiretroviral drugwww.sciencedirect.com from a different class to an optimal ART regimen should
produce a decline in residual viremia detectable with
such assays. If, on the other hand, residual viremia simply
represents release of virus from stable reservoirs, then
intensification should not decrease residual viremia. As
shown in Figure 1, none of the current antiretroviral drugs
block release of virus from cells that have an integrated
provirus. Thus the activation of a small fraction of the
resting CD4+ T cells that harbor latent HIV-1 could result
in trace levels of viremia that would not be affected by
treatment intensification. Over the last several years,
numerous intensification studies have been carried out
with different intensification drugs [30–33]. The results
have been remarkably consistent. All studies show that
intensification has no effect on residual viremia. This
means that residual viremia is largely due to release of
virus from stable reservoirs, and that if there is ongoing
replication, it results in a level of viremia that is insig-
nificant even compared to the trace levels detected with
the single copy assay. A recent study has shown that
intensification also fails to reduce trace levels of HIV-1
RNA in the cerebrospinal fluid [34].
Direct studies of viral evolution in patients on ART are
complicated by the very low levels of virus present in the
blood but have generally not shown any evidence for
evolutionary change even over long time intervals. In
some cohort studies, a small subset of the patients show
evidence of viral evolution [35,36], but it cannot be
excluded that these were patients with poor adherence.
No study has documented ongoing viral evolution in the
setting of adequate drug levels, and most patients show a
striking lack of evolutionary change in viral sequences.
The residual viremia is composed of drug sensitive
viruses that do not evolve over time [37–41]. In acute
infection, the gut associated lymphoid tissue (GALT) is a
major site of viral replication [42], and high levels of HIV-
1 DNA are found in CD4+ T cells in the GALT even in
treated patients [43]. A recent study has shown that even
in the GALT, there is no detectable viral evolution in
patients on ART, while evolution is readily detectable in
untreated patients [44].
Recent studies of HIV-1 pharmacodynamics have pro-
vided a quantitative basis for understanding the ability ofCurrent Opinion in Virology 2013, 3:487–494
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refers to the relationship between drug concentration
and drug effect. The most commonly used pharmacody-
namic parameter is the IC50, the drug concentration at
which there is 50% inhibition of some measure of viral
replication. The fraction of infection events affected
(inhibited) by a drug ( fa) at a given concentration D is
related to the IC50 by the median effect equation [45]:
f a ¼
1
1 þ ðIC50=DÞm
where m is a measure of the slope or steepness of the
dose–response curve. This slope parameter has an expo-
nential relationship to drug effect, and when the
D > IC50, slope values greater than 1 can produce extre-
mely high levels of inhibition. The slope parameter is
related to the Hill coefficient, a measure of cooperativity,
and slope values >1 are typically associated with coop-
erative binding of ligands to a multivalent receptor.
However, the molecular targets of most antiretroviral
drugs are monovalent with respect to inhibitors, and
thus high slope values were not expected for antire-
troviral drugs. In 2008, Shen et al. showed that some
classes of antiretroviral drugs, notably the NNRTIs and
the PIs, show highly cooperative dose response curves
with high slope values in the inhibition of infectivity
[45]. These high slopes allowed clinical concentrations
of these drugs to produce many logs of inhibition of
viral replication. When the combined effects of
multiple drugs used together in ART regimens
were considered, it became clear that most ART
regimens could produce levels of inhibition that
were consistent with a complete block in ongoing
replication [46].
One particularly interesting argument supporting the
efficacy of ART in blocking new infection involves
recent reports of potential cures. The original report
described the ‘Berlin patient’, an HIV-1-infected man
who had sustained suppression  of viremia on ART
when he developed acute myeloid leukemia [47]. As
part of the treatment for leukemia, he received two
hematopoetic stem cell (HSC) transplants from a donor
who was homozygous for a 32 base pair deletion in the
HIV-1 co-receptor CCR5. ART was discontinued at the
time of the initial transplant, and viremia never
rebounded. A recent exhaustive study of multiple tis-
sues from this patient five years after the initial trans-
plant failed to uncover consistent evidence of viral
persistence [48]. In this case, donor cells were pro-
tected from infection by the absence of CCR5. Two
additional cases of HSC transplantation have recently
been reported, and in these cases the donors were wild
type for CCR5 [49]. In these cases, the donor cells
were protected from HIV-1 infection by ART, which
was continued uninterrupted throughout the entire
transplant period. HIV-1 became undetectable at theCurrent Opinion in Virology 2013, 3:487–494 time when 100% chimerism was documented. It
remains to be determined whether these two new cases
actually represent cures, but if so, they would dramatic-
ally illustrate the ability of ART to prevent otherwise
susceptible donor cells from HIV-1 infection.
Although the preponderance of evidence suggests that
modern ART regimens can arrest HIV-1 evolution in
adherent patients, there is some evidence that trace
amounts of replication continue. Patients on ART do
experience higher levels of immune activation and higher
rates of some non-infectious complications [50]. There is
concern that some level of replication continuing in
particular compartments could contribute to these com-
plications and account for differences in life expectancy
between patients and uninfected individuals. However,
studies of this kind are complicated by differences in
other risk factors in patient populations, legacy effects
persisting from the time before treatment, and by drug
toxicity.
Another line of evidence supporting some degree of
ongoing replication is a recent study of the effects of
intensification with the InSTI raltegravir [51]. Although
levels of residual viremia did not change with intensifica-
tion, there was a transient increase in the level of 2LTR
circles, especially in patients on PI-based regimens. The
circles form in the nucleus of infected cells when integ-
ration fails and the reverse transcribed HIV-1 DNA under-
goes an end to end intermolecular ligation. The increase in
these circles suggests that there were some new infection
events in which virions released from an infected cell
successfully matured and infected another cell in which
reverse transcription then proceeded to completion. It is
currently unclear how to reconcile this result with the
evidence against ongoing replication presented above.
Finally, a scenario in which replication could continue
despite ART has recently been described by Sigal and
Baltimore [52]. These investigators have shown that the
local spread of HIV-1 from an infected cell to a neighbor-
ing cell can involve very high multiplicities of infection,
which from a simple probability standpoint reduces the
effectiveness of antiretroviral drugs. This finding raises
the possibility of local bursts of new infection, perhaps
initiated by reactivation of latently infected cells.
Failure without resistance
An interesting development in the analysis of HIV-1 drug
resistance is the phenomenon of treatment failure with-
out resistance [53,54]. Some patients on PI-based
regimens develop detectable viremia but do not have
resistance mutations in HIV-1 protease. Of course, non-
adherence is one simple explanation, but in many cases
the patients do show resistance to other drugs in the
regimens. Two recent studies have offered potential
explanations for PI failure without resistancewww.sciencedirect.com
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Explanations for PI failure without resistance mutations in the protease
gene. (a) Pharmacodyamic properties of PIs restrict the evolution of
resistance. During periods of non-adherence, resistant viruses emerge.
As drug concentrations fall, there is a mutant selection window (MSW) in
which the mutant virus has both a positive growth rate (R0 > 1) and a
selective advantage over wild type virus. The length of the MSW
depends on drug half-life, the properties of the dose-response curves for
wild type (green) and resistant (red) viruses, and the fitness cost of the
resistance mutation. For PIs, the time spent in the MSW is extremely
short and with non-adherence, wild type virus rapidly emerges. Note that
this form of treatment failure does not represent drug resistance, and
suppression of viremia can be achieved by restoring adherence. (b)
Mutations inside of (red) and outside of (*) the protease coding region
can contribute to resistance. As shown in Figure 1, part of the inhibitory
effect of PIs is due to effects on HIV-1 entry. Interactions between the
uncleaved Gag precursor protein and the cytoplasmic domain of the Env
protein inhibit entry, and thus PI-mediate inhibition of Gag cleavage
results in inhibition of infectivity. Resistance to PIs may arise through
mutations affecting the Gag–Env interaction. Mutations in the protease
cleavage sites in Gag can also contribute to resistance. Current clinical
assays for PI resistance examine only the protease gene and could miss
other mutations contributing to resistance.(Figure 2). Rosenbloom et al. used pharmacokinetic and
pharmacodynamics parameters and data on the fitness
cost of resistance mutations to show that the time spent in
the mutant selection window (MSW) is short for PIs [55].
The MSW refers to the time following treatment inter-
ruption during which a drug resistant mutant has both a
positive growth rate and a selective advantage over wild
type virus. In evolutionary terms a positive growth rate is
indicated by R0 > 1, where R0 is the basic reproductive
ratio, the number of new cells that are infected by the
virus released from a single infected cell. At very high
drug concentrations, the resistant virus will be inhibited
to a lesser extent than wild type virus but may still be
unable to grow (R0 < 1). As the drug concentration falls
with non-adherence, it will reach a level at which thewww.sciencedirect.com mutant will have a positive growth rate (R0 > 1). This
defines one boundary of the MSW (Figure 2a). Most
drug resistance mutations cause a reduction in viral
fitness in the absence of drug, and therefore the drug
concentration will fall to a point where the wild type
virus has a higher replication rate than the mutant virus.
This defines the other boundary of the MSW. At drug
concentrations within this window, the mutant virus
will be selected. The time spent in the MSW after
treatment is interrupted is a complex function of the
drug half-life, and the effect of the resistance mutations
on IC50, m, and viral fitness. Recent studies indicate
that for PIs, the time spend in the mutant selection
window is extremely short [54]. With falling PI con-
centrations, wild type virus rapidly gains a selective
advantage, and thus patients can fail due to non-adher-
ence without developing resistance.
Recent studies have uncovered a second explanation for
the phenomenon of failure without PI resistance [56]. As
discussed above, PIs are extremely effective antiretroviral
drugs due to highly cooperative dose–response curves
that are not fully explained by current pharmacodynamic
theory [45,57]. The nature of these curves as well as the
phenomenon of PI failure without resistance can both be
explained through analysis of the effects of PIs on distinct
steps in the life cycle (Figure 1). PIs do not affect virion
release from infected cells but block entry, reverse tran-
scription (RT), and post-RT steps [56]. The overall
dose-response curves can be reconstructed by combining
the curves for each step using the Bliss independence
principle. Thus independent inhibition of multiple dis-
tinct steps in the life cycle generates the highly coopera-
tive dose–response curves that make these drugs
uniquely effective. Approximately half of the inhibitory
potential of PIs is manifested at the entry step, likely
reflecting interactions between the uncleaved Gag and
the cytoplasmic tail (CT) of the Env protein [58].
Sequence changes in Env, which are ignored in current
clinical tests for PI resistance, can confer PI resistance,
providing an explanation for PI failure without resistance.
Mutations in the HIV-1 protease cleavage sites in the Gag
polyprotein can also be selected for during PI failure
[59]. Thus some cases of PI failure without resistance
mutations in the protease gene may actually represent the
evolution of resistant viruses that have sequence changes
in other genes that contribute to PI resistance. Because
current clinical tests for PI resistance consider only the
protease gene itself, this issue deserves additional
exploration.
Conclusions
Recent clinical experience and experimental studies have
clearly shown that HIV-1 infection can be successfully
treated without the evolution of drug resistance. The
underlying explanation for this development is the ability
of current ART regimens to suppress viral replication toCurrent Opinion in Virology 2013, 3:487–494
492 Antivirals and resistancesuch a great extent that the evolution of drug resistance,
which depends on new infection events, is essentially
halted.
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